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ABSTRACT 
Cancer stem cells (CSCs) or tumor initiating cells are rare cells that are able to establish a tumor or metastasis. Identi-
fication of those CSCs is, however, cumbersome even in established cell lines. Several cancer stem cell markers were 
reported to be expressed by ovarian cancer. Those cancer stem cells are gifted with lower vulnerability to irradiation 
and cytostatic drugs explaining the high incidence of recurrence after treatment. A variety of different cancer stem cell 
markers were described for epithelial tumors. Also, cancer cell lines were assessed for stem cell markers with no com-
mon denominator. The expression of CD24, CD44, CD117, CD133, ABCG2, ALDH was determined for cells from 22 
patients. Ovarian cancer cells were collected from ascites. Part of the tumor cells were analyzed immediately and 
stained for the above mentioned cancer stem cell markers. The remainder of the cells was cultured for several weeks 
using standard stem cell culture conditions. We observed a large variety in expression of putative stem cell markers for 
primary tumors. After two weeks of culture spheres were seen in several cultures, indicative for cancer stem cells, 
though not all patients’ cells were able to form spheres. Our data show for the first time the heterogeneity in marker 
display in primary tumors. Also for the cultured cells stem cell markers were determined. None of the stem cell markers 
was expressed by all patients’ cells. No correlation with tumor type was demonstrated. The complexity of expression 
challenges the isolation of cancer stem cells. 
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1. Introduction 
Ovarian cancer is the fifth leading cause of death from 
cancer in women and the most lethal gynecological ma-
lignancy. It has a poor prognosis due to late patient 
presentation because early symptoms are not evident or 
vague and confused with more common gastrointestinal 
diseases. The incidence of ovarian cancer is approxi-
mately 1 in 60 women. When diagnosed early the sur-
vival is far better than at advanced stages of the disease, 
at which point the 5-year survival is only 30%. Moreover, 
the development of a chemoresistant tumor after surgery 
and chemotherapy aggravates the situation. Novel treat-
ment modalities are needed to increase the survival rate.  
Targeting the cancer stem cell (CSC) has been put  
forward as such a new treatment modality [1,2]. How-
ever, the CSC concept is heavily debated. The CSC is a 
relatively rare cancer cell that has the ability to 
self-renewal giving rise to another malignant stem cell as  
well as commit to terminal differentiation into multiple 
lineages of more mature cancer cells [3-6]. The differen-
tiated cells constitute the bulk of the tumor, but they lack 
self-renewal capacity and have limited proliferation po-
tential.  
Increasing experimental evidences suggest that CSCs 
may play a decisive role in the initiation and progression 
of tumors [7]. CSCs were originally identified in leukemia, 
Bonnet and co-workers demonstrated that human leuke-
mias are driven by a small population of leukemic stem 
cells capable of transferring the disease to NOD/SCID 
mice [8]. This concept was extended to solid epithelial 
tumors by Al-Hajj and co-workers, who demonstrated that 
a small population of cells within breast cancer with stem 
cell properties, bearing the surface marker CD24lowCD44high. 
Subsequently, CSCs are identified and prospectively iso-This study was supported by a grant from the Netherlands Institute for Regenerative Medicine.  
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lated from a variety of epithelial cancers, including pan-
creas, colon and prostate cancers [5,9-15]. The cancer 
stem cell hypothesis has recently also been explored in 
ovarian cancer. In 2008, Zhang and co-colleagues claimed 
that epithelial ovarian cancers derive from a subpopulation 
of CD44+CD117+ cells [16]. Recently, Ferrandina and 
Curley independently found that CD133 expression de-
fines a tumor initiating subpopulation of cells in human 
ovarian cancer [17,18]. Moreover, Gao and co-workers 
reported that CD24 could be utilized as a surface marker 
to enrich ovarian CSCs [19]. Ovarian CSCs were also 
detected in the so-called side populations, which are tu-
morigenic and chemoresistant [20-22]. The hypothesis that 
CSCs are responsible for tumor recurrence and metastasis 
of ovarian cancer gets more and more support. If indeed 
CSCs are the targets to treat ovarian cancer, novel strate-
gies have to be developed to target specifically those cells. 
Current chemotherapeutic drugs do not kill CSCs because 
those stem cells express several pumps, for instance 
ABCG2, that expel cytostatic drugs out of the cell [22,23]. 
In the current study, we tested the expression of the 
described putative epithelial CSC markers in primary 
ovarian tumor ascites, in order to assess whether they can 
be utilized as general markers to identify and isolate ova-
rian CSCs. Our data shows that the expression of those 
CSC markers is very diverse and is patient-dependent, 
and no correlation was found between pattern of surface 
marker display and tumor histologicalsubtype. These 
suggest that ovarian tumors are heterogeneous, and a 
more general marker is needed to prospectively isolate or 
target ovarian CSCs for elimination. 
2. Materials and Methods 
2.1. Primary Tumor Sphere Culture 
Freshly-isolated ascites fluid was received from the De-
partment of Obstetrics and Gynecology, Radboud Uni-
versity Nijmegen Medical Centre. Following filtration 
through a 100 μm cell strainer (BD FalconTM), viable 
ascites-derived mononuclear cells were isolated by cen-
trifugation over LymphoprepTM (Axis-Shield). The as-
cites-derived mononuclear cells were suspended in 
GIBCO™ Defined Keratinocyte-SFM (1x; Invitrogen) 
supplemented with recombinant human EGF (20 ng/ml; 
R&D systems) and plated at a density of 2 × 106 tumor 
cells/24 well plate with Ultra-Low Attachment surface 
(Corning Incorporated). Cells were grown at 37°C with 
5% CO2 [24]. 
2.2. Aldefluor Assay 
ALDEFLUOR assay was performed with the ALDE-
FLUOR kit from Stem Cell Technologies. Prior to treat-
ment, cells were suspended in aldefluor assay buffer (1 × 
106cells/ml). aldefluor assay reagent containing the ALDH 
substrate BODIPY-aminoacetaldehyde (BAAA) was added 
to both control and test samples (5 µl/ 1 × 106cells). Be-
fore addition of BAAA, the negative control sample was 
treated with a specific inhibitor of ALDH, diethylaminoben-
zaldehyde (DEAB, 5 µl/ 5x105cells). Then the samples were 
incubated for 45minutes at 37oC to allow conversion of 
the substrate BAAA to the fluorescent product 
BODIPY-aminoacetate (BAA). The amount of intracellu-
lar fluorescent product was then measured using a 
CyAnTM ADP flow cytometer (Beckman Coulter). 
2.3. Immunofluorescence Staining and 
Microscopy 
ALDEFLUOR treated cells were rinsed in PBS, and 
then cells were adhered to poly-L-lysine-coated cover 
slips and fixated with 2% PFA in PBS for 15 minutes. 
Cover slips were mounted onto glass slides with Mo-
wiol. Subsequently, cells were examined by fluores-
cence microscopy (Olympus).  
2.4. Flow Cytometric Analysis of Cancer Stem 
Cell Markers 
Cells were isolated from ascitic fluid and cultured for 
two weeks in stem cell medium. To stain for cell surface 
markers, washed with PBA (PBS/0.1% BSA/0.1% so-
dium azide) and incubated with the following antibodies 
at 4°C for 30 minutes: CD24-PE (Beckman Coulter), 
CD44-APC (BD PharmingenTM), c-Kit-FITC (CD117) 
(Santa Cruz Biotechnology), CD133-PE (Miltenyi Bio-
tec), ABCG2-PE (R&D Systems). Before flow cytomet-
ric analysis the cells were washed and resuspended in 
PBA solution. Cells were then examined using the 
CyAnTM ADP flow cytometer. The exitation wavelenght 
for FITC was 488 nm and emission wavelenght 530 nm, 
for phycoerythrin excitation at 561 nm and emission at 
585 nm and for allophycocyanin excitation at 643 nm 
and emission at 665 nm. 
3. Results 
3.1. Self-renewing Spheres Are Not Formed in 
All Patients with Ovarian Cancer 
One key determinant of stem cells is the capability for 
extensive proliferation. To demonstrate whether cells 
with distinct proliferation abilities were present in human 
ovarian tumors, we established cultures with as-
cites-derived tumor cells from 22 ovarian cancer patients. 
(Table 1). To assess the formation of tumor spheres, 
freshly isolated as well as frozen tumor cells were cul-
tured under conditions proved to favor the growth of 
stem cells [16,25-27]. By this approach, we found that 
not all of the ascites yielded tumor spheres during pri-  
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Table 1. Summary of patient population. 
Ptn 
No. 
Age 
FIGO 
stage 
Histological subtype 
Sphere 
formation 
4 61 III Serous Yes 
10 85 III Adenocarcinoma* Yes 
14 81 III Adenocarcinoma* No 
15 62 Ic Endometrioid Yes 
17 57 III Serous No 
19 33 III Mucinous No 
20 73 III Serous Yes 
21 64 III Serous No 
23 57 IV Serous No 
30 46 III Adenocarcinoma* Yes 
31 67 IV Serous No 
33 84 III Serous Yes 
35 95 III Sarcoma No 
36 77 IV Serous No 
37 69 III Serous No 
41 36 III Mucinous No 
44 69 III Serous No 
45 77 III Serous Yes 
50 58 III Adenocarcinoma* No 
51 52 Ic Mucinous Yes 
52 63 III Adenocarcinoma* No 
55 63 III Serous Yes 
*: Histological subtype undefined; Ptn No.: patient number 
 
mary culture for 2 weeks. Regardless of histological sub-
types, only the cells from 9 out of the 22 patients were 
capable of generating sphere-like clusters (Table 2). 
3.2. Expression of Putative Ovarian CSC  
Markers Are Diverse Among Patients 
Ovarian CSCs were identified and prospectively isolated 
by several cell surface markers, including CD44+CD117+, 
CD133+ and CD24+ [16,27]. To investigate whether 
these markers are generally functional to isolate CSCs 
from all ovarian cancer patients, we cultured the as-
cites-derived tumor cells for 2 weeks and analyzed CSC 
marker expression by flow cytometry (Figure 1). Re-
markably, we found that the expression pattern of these 
CSC markers was different among patients, and the ex-
pression of those markers was not associated with histo-
logical subtype of the patients. Moreover, we found no 
correlation between expressions of any of these CSC 
markers with the ability of tumor sphere formation.  
We found cells from only 2 out of 11 patients expressed 
CD133, of which one patient had 73.3% while the other 
had only 3.7% CD133+ cells. Both tumors were classified 
as serous adenocarcinoma. We also found that cells from 
all the 13 analyzed patients expressed CD24, although the 
CD24+ cells ranged from 3.2% to 86.7%. Similarly, CD44 
was also widely expressed, ranging from 2.2% to 88.2%.  
Table 2. Statistics of patient population (n = 22). 
Age 33-95 64 (median) 
Ic 2 
III 17 FIGO stage 
IV 3 
Serous 12     
Mucinous 3 
Endometrioid 1 
Adenocarcinoma* 5 
Histologic  
subtype 
Sarcoma 1 
Included Ptn No.: 4, 10, 14, 15, 17, 19, 20, 21, 23, 30, 31, 33, 35, 36, 37, 41, 
44, 45, 50, 51, 52, 55; *: Histological subtype undefined 
 
Cells from only 1 in 13 patients had no CD44 expression 
and 2 out of 13 patients had very low CD44 expression. 
Interestingly, 2 of the 3 patients were diagnosed with 
mucinous adenocarcinoma while the other patient was 
difficult to be classified into histological subtype. In 
contrast to CD24 and CD44, the rare population of 
CD117+ cells was detected in 7 out of 11 patients, rang-
ing from 2.9% to 11.2%. We detected a low percentage 
(<2%) of CD44+CD117+ cells in 3 out of 6 patient ascites 
fluids. In addition to the CD44+CD117+ cell population, 
we also observed patients with CD44+CD117- cells as well 
as patients with CD44-CD117+ cell populations in the same 
histological subtype. Moreover, ABCG2 has been found 
over-expressed in CD133+ sphere-forming cells in ovarian 
cancer patients [16], and is believed to be associated with 
chemo-resistance. We therefore examined whether it is 
up-regulated in all ovarian cancer patients. We stained as-
cites-derived tumor cells after primary culture and test 
with the expression of surface markers, ABCG2 was also 
not detected in all the patients. We only observed a slight 
increase of ABCG2 expression (< 1%) in 1 out of the 13 
patients. 
Table 3. Overview of ALDH expression. 
 Percentage of gated ALDH+ cells in Region 2 
 Before culture After primary culture 
Ptn 
No. 
With 
DEAB 
Without 
DEAB 
With 
 DEAB 
Without 
DEAB 
4 0.02 1.18 0.03 0.44 
9 0.02 0.65 0.02 0.17 
10 0.02 6.99 0.02 0.18 
17 0.01 1.32 - - 
19 - - 0.01 2.54 
20 0.02 0.38 0.02 0.05 
21 - - 0.02 0.54 
23 0.03 3.93 0.03 0.85 
30 0.01 2.74 0.01 0.01 
33 - - 0.02 1.07 
35 0.01 1.65 - - 
36 0.03 3.00 0.03 0.08 
42 - - 0.03 0.05 
45 0.01 1.39 0.01 0.76 
50 0.03 0.18 0.03 1.29 
51 0.01 4.86 0.01 0.01 
52 0.02 0.72 0.02 0.08 
-: Data not available;Data displayed in percentage of positive cells; Ptn No.: 
patient number 
Expression Compilation of Several Putative Cancer Stem Cell Markers by Primary Ovarian Carcinoma 
Copyright © 2010 SciRes.                                                                                  JCT 
168 
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(b) 
Figure 1. Expression of putative ovarian CSC markers. A. Isotype controls are indicated by the grey lines. B. Double staining 
of CD44 and CD117 for several patients tumor cells. 
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(a) 
 
 
(b) 
Figure 2. ALDH-positive cells are reduced during primary culture. A. Representative flow cytometry analysis of ascites-derived 
ovarian tumor cells using the ALDEFLUOR assay. Cells were incubated with ALDEFLUOR substrate BAAA and the specific in-
hibitor of ALDH, DEAB, for ~45 min. Gates were set according to DEAB control (ALDH+ cells ≤ 0.03%). B. ALDH 1 staining of 
ascites-derived tumor cells before culture. ALDH 1 positive cells were very bright comparing to DEAB treated cells. ALDH 1 stain-
ing of ascites-derived tumor cells after primary culture for 2weeks. The signal intensity of ALDH 1 positive cells was reduced. 
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3.3. Aldehyde Dehydrogenase 1 (ALDH1)  
Expression/activity Is Changed in Ovarian  
Cancer Patient upon Culturing. 
ALDH1 is expressed in stem and progenitor cells of sev-
eral tissue types, including CSCs. ALDH1+ cells are en-
riched in colon, breast and ovarian cancers. It predicts 
poor clinical outcome in breast cancer while correlates 
with poor and favorable prognosis in ovarian cancer 
[28,29]. So we wondered whether ALDH1 can be ap-
plied to identify ovarian CSC in cells isolated from as-
cites. We utilized the ALDEFLUOR assay to assess the 
presence and expression of the population with ALDH1 
enzymatic activity in ascites-derived tumor cells before 
and after primary culture of 2 weeks. Analysis of freshly 
isolated as well as frozen tumor cells from different pa-
tients showed an average of 2% (2.2% ± 2.0, n = 13) 
ALDH1-positive population. However, after 2 weeks of 
culture the ALDH1-positive cells were reduced to 1% 
(0.5% ± 0.7 n = 15) (Figure 2, Table 4). Among the 15 
patients tested after primary culture, 14 of them showed 
significant decrease in ALDH1 expression comparing to 
fresh cells, while only 1 patient showed up-regulation of 
ALDH1. Moreover, we also found that ALDH1 signal 
intensity was reduced upon culturing under confocol 
microscopy, (Figure 2). From these results we conclude 
that ALDH1 cannot be used as a functional marker to 
enrich ovarian CSCs. 
4. Discussion 
The CSC hypothesis has fundamental implications for 
cancer biology in addition to clinical implications for 
cancer elimination. The development of novel cancer 
therapeutics requires targeting this important CSC popu-
lation, to prevent tumor relapse. The success of these 
new approaches is based on defining the ‘real’ CSCs. 
Several criteria have been established to identify, isolate 
and characterize CSCs, including self-renewal tumor 
sphere formation and expression of distinct cell surface 
antigens, permitting consistent isolation. And based on 
these criteria, putative ovarian CSCs have been identified 
and prospectively isolated from patient ascites, ovarian 
cancer cell lines, primary tumor tissues as well as mouse 
cell lines. They all proved that only a small subpopula-
tion of tumor cells bearing certain surface makers are 
capable of self-renewal, and are capable of initiating and 
supporting the malignant tumor growth. We did a large 
study with ascites derived from 22 ovarian cancer pa-
tients and for the first time revealed that, due to hetero-
geneity of patients, expression of the putative ovarian 
CSC makers are not applicable to isolate CSCs from all 
patients.  
Firstly, our study showed that not cells from all pa-
tients are capable of anchorage-independent growth and 
three-dimensional tumor sphere formation in stem cell 
culture media. This sphere formation difference could be 
explained by the origin of CSCs in the patients. There are 
two hypothesis elucidate the origin of CSCs, one claims 
that CSCs are generated from transformed normal stem 
cells, so that they can make use of the already active 
self-renewal machinery. The other claims that CSCs are 
generated from progenitor cells by regaining the self-renew 
pathway. We envisage that normal stem cell-derived CSCs 
are capable of sphere formation, whereas progeni-
tor-derived ones are not. Moreover, it is also possible 
that the amount of malignant CSCs in some patients was 
not sufficient to form tumor spheres, and the tumorigenic 
capacity of the CSCs from each patient is different. 
However, we cannot exclude that current culture condi-
tions based on other epithelial tumors are not optimal yet 
for the proliferation of ovarian CSCs from all patients. 
Interestingly, we found cells from patients of FIGO stage 
I could form tumor spheres, indicating the existent of 
CSCs at the initiating stage of malignant tumor growth. 
Such a concept has important ramifications. It lends 
support to the hierarchy model of tumor heterogeneity, 
meaning that only a small subpopulation of malignant 
cells is responsible for tumor initiation. 
Secondly, we demonstrated that those putative makers 
are also not applicable to isolate CSCs from all primary 
ovarian tumors, since their expression differs dramatically 
among patients. For instance, we showed that CD133 
was only detected in 2 patients; we found that CD24 and 
CD44 were expressed by almost all the patients analyzed, 
whereas the cell populations bearing CD24 or CD44 in 
most patients were too large to be considered as malig-
nant stem cells; we also revealed that CD44+CD117+ 
populations were detectable in only 3 out of 7 patients. 
Consistently, recent studies using ovarian tumor cell 
lines as well as primary tumor specimens revealed that 
putative CSC markers, including ALDH are displayed in 
a complex pattern [30]. In one study using the NCI60 
tumor cell line panel , it is found that expression of 
CD44, CD24, and CD133 varied greatly even between 
cell lines of the same tumor type [31]. In the same study, 
they demonstrated cell populations with ALDH activity 
ranged widely, from 0 up to 38.8%. In order to increase 
understanding of how to target and ultimately eradicate 
an ovarian CSC population, researchers make use of dif-
ferent ovarian tumor materials to isolate those cells from 
the bulk of cells. However, our results suggest that ovar-
ian cancers are very heterogeneous, study material has a 
profound influence on the putative markers identified. 
The complexity of marker expression suggests that the-
rapeutic targeting utilize of different tumor materials 
could result in different putative CSC populations bear-
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ing distinct surface markers. Future studies aiming to 
isolate CSCs have to take this into account. 
Moreover, we found that expression of putative ovar-
ian CSC markers neither correlate with clonogenic ca-
pacity of ascites-derived tumor cells, nor associate with 
patient histosubtypes. Studies have shown that a small 
percentage of CD24+, or CD133+ cells or CD44+CD117+ 
cells isolated from ovarian tumor specimens or ovarian 
tumor cell lines were considered ovarian cancer-initiating 
cell populations. They proved that only a small percent-
age of isolated cells bearing one of those markers were 
able to form colonies in vitro, indicating that tumors are 
composed of biologically and functionally distinct cell 
populations. And they demonstrated that cells within the 
tumorigenic clones bear stem cell properties and are ca-
pable of transferring the disease into nude mice[19]. 
However, we found that CD24 was expressed in cells 
from all tested patients. 2 out of 13 patients were bearing 
rare populations of CD24+ cells (< 10%), of which one 
patient had tumor sphere formation in vitro while the 
other had not. Whereas 4 out of 13 patients were with 
extremely large CD24+ populations (> 60%), of which 
cells from 2 patients formed in vitro spheres but the oth-
ers did not. Moreover, in our study CD133 expression 
was detected in cells from 2 out of 11 analyzed patient 
ascites, belonging to the serous subtype. One of the 2 
patients with large CD133+ population (73.3%) formed 
tumor sphere while the other patient with 3.7% CD133+ 
cells did not. And in our hands only 3 patients were con-
taining CD44+CD117+ cells are restricted to FIGO stage 
III serous adenocarcinoma, although the patient with 
lowest CD44+CD117+ cell population did not generate 
tumor spheres. Collectively, these results again indicate 
that ovarian cancers are very heterogeneous, and even 
tumors with the same phenotypes might originate from 
distinct populations of CSCs. These observations indeed 
indicate that those putative markers cannot be used as a 
general target to enrich for ovarian CSCs from all histo-
logical distinct patients. 
In addition to the surface markers, we showed that 
ABCG2 expression was only detectable in 1 out of 11 
analyzed patient ascites, suggesting that ABCG2 is not 
necessarily the efflux transporter functional in all the 
ovarian cancer patients; we cannot exclude the existence 
and functions of other membrane transporters in che-
mo-resistance. 
Finally, we showed that ALDH1 expression or its ac-
tivity was changed after primary culture, indicating that 
it is not a valid marker for ovarian CSC. However, the 
reason why ALDH1 expression was reduced upon cul-
turing remains unclear. It has been show that ALDH1 is 
a predictor of favorable prognosis in ovarian cancer by 
immunohistochemical staining of ALDH1 expression in 
a large number of primary ovarian carcinomas [29]. In 
contrast, another study reported that higher ALDH1 ex-
pression is significantly associated with poor clinical 
outcome in serous ovarian cancer.[28] Our study again 
suggests that different histological type ovarian epithelial 
tumors have remarkably distinct molecular background. 
Therefore, the prognostic value of ALDH1 in ovarian 
cancer still needed to be further investigated. 
Here we studied primary cells obtained from ascites of 
ovarian cancer patients. It remains to be proven that the 
cells present in the ascites are a reflection of the cells 
present in the tumor mass. Since stem cells are found in 
so-called niches and cells in the ascites lost contact with 
their niche it cannot be excluded that cells in the ascites 
fluid are not equivalent to the tumor cells in the solid 
tumor [32]. However, tumor spread in the abdomen of 
the patients is likely to proceed from ascites cells pre-
dicting the presence tumor initiating cells in ascites. 
Taken together, our study revealed that ovarian cancer 
is a heterogonous disease [33] and all the reported puta-
tive ovarian CSC markers are not applicable to isolate 
CSCs from all patients. This distinct marker expression 
may due to the difference between tumor cell lines and 
primary tumor materials. Thus, a universal target to iso-
late ovarian CSCs is required to facilitate tumor elimina-
tion, using ‘representative’ patient materials. 
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